# A Clinical Study to Investigate the Efficacy of Tigilanol Tiglate Directly in Head and Neck Cancer

Source: https://onco.cc/trials/nct05608876/  
OnCo record `nct05608876` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Tigilanol Tiglate in head and neck squamous cell carcinoma, run by QBiotics Group Limited, active and no longer recruiting.

## Summary

A Clinical Study to Investigate the Efficacy of Tigilanol Tiglate Directly in Head and Neck Cancer is a phase 2 interventional study registered as NCT05608876 by QBiotics Group Limited, with 15 participants enrolled, started 2022-11-03 and due to reach its primary completion in 2025-07-31. Interventions recorded: Tigilanol Tiglate.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05608876
- Phase: 2
- Setting: A Phase II, Open Label, Single Arm Study To Assess The Efficacy Of Intratumoral Tigilanol Tiglate In Various Head And Neck Solid Malignancies
- Sponsor: QBiotics Group Limited
- Enrolled: 15

## Sources

- ClinicalTrials.gov NCT05608876: https://clinicaltrials.gov/study/NCT05608876

## Connected records

- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/)
- companies: [QBiotics](https://onco.cc/companies/qbiotics/)

---
JSON: https://onco.cc/api/v1/entities/nct05608876.json